
Opinion|Videos|September 20, 2024
Future Directions in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
Advertisement
Episodes in this series

- How do you see the treatment landscape for mCRPC evolving in the coming years?
- What advice would you offer community oncologists for staying up to date with the rapidly changing field of mCRPC management?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5

















